Long-term clinical outcomes in cirrhotic chronic hepatitis B patients treated with tenofovir disoproxil fumarate for up to 5 years

Hepatology International

Volumn 9, Issue 2, 2015, Pages 243-250

  Buti, Maria ^a   Fung, Scott ^b   Gane, Edward ^c   Afdhal, Nezam H ^d   Flisiak, Robert ^e   Gurel, Selim ^f   Flaherty, John F ^g   Martins, Eduardo B ^g   Yee, Leland J ^g   Dinh, Phillip ^g   Bornstein, Jeffrey D ^g   Mani Subramanian, G ^g   Janssen, Harry L A ^h   George, Jacob ⁱ   Marcellin, Patrick ^j  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b UNIVERSITY OF TORONTO   (Canada)

^c AUCKLAND CITY HOSPITAL   (New Zealand)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^e MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^f ULUDAG UNIVERSITY   (Turkey)

^g GILEAD SCIENCES   (United States)

^h ERASMUS MEDICAL CENTER   (Netherlands)

ⁱ UNIVERSITY OF SYDNEY   (Australia)

^j BEAUJON HOSPITAL   (France)

more..

Author keywords

Antiviral agent; Chronic hepatitis B; Cirrhosis; Hepatitis B e antigen; Hepatitis B surface antigen; Tenofovir disoproxil

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIVIRUS AGENT; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; TENOFOVIR;

ADULT; BLOOD; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECTS; FEMALE; HEPATITIS B, CHRONIC; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TUMOR; MALE; PATHOLOGY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; TIME FACTOR; VIROLOGY; VIRUS LOAD;

ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; RETROSPECTIVE STUDIES; TENOFOVIR; TIME FACTORS; VIRAL LOAD;

EID: 84939983283     PISSN: 19360533     EISSN: 19360541     Source Type: Journal    
DOI: 10.1007/s12072-015-9614-4     Document Type: Article

References (19)

1. Lok AS. Chronic hepatitis B. N Engl J Med 2002;346:1682–1683
2. Brown A, Goodman Z. Hepatitis B-associated fibrosis and fibrosis/cirrhosis regression with nucleoside and nucleotide analogs. Expert Rev Gastroenterol Hepatol 2012;6:187–198
3. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295:65–73
4. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006;130:678–686
5. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009;50:661–662
6. Dienstag JL, Goldin RD, Heathcote EJ, Hann HW, Woessner M, Stephenson SL et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 2003;124:105–117
7. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis b for up to 5 years. Gastroenterology 2006;131:1743–1751
8. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351:1521–1531
9. Schiff ER, Lee SS, Chao YC, Kew Yoon S, Bessone F, Wu SS et al. Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B. Clin Gastroenterol Hepatol 2011;9:274–276
10. Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 2013;381:468–475
11. Heathcote EJ, Marcellin P, Buti M, Gane E, De Man RA, Krastev Z et al. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology 2011;140:132–143
12. Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008;359:2442–2455
13. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696–699
14. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007;132:2557–2576
15. Goldstein ST, Zhou F, Hadler SC, Bell BP, Mast EE, Margolis HS. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int J Epidemiol 2005;34:1329–1339
16. Hyun JJ, Seo YS, Yoon E, Kim TH, Kim DJ, Kang HS et al. Comparison of the efficacies of lamivudine versus entecavir in patients with hepatitis B virus-related decompensated cirrhosis. Liver Int 2012;32:656–664
17. Chen YC, Chu CM, Yeh CT, Liaw YF. Natural course following the onset of cirrhosis in patients with chronic hepatitis B: a long-term follow-up study. Hepatol Int 2007;1:267–273
18. Seto WK, Liu K, Wong DK, Fung J, Huang FY, Hung IF et al. Patterns of hepatitis B surface antigen decline and hbv DNA suppression in Asian treatment-experienced chronic hepatitis B patients after three years of tenofovir treatment. J Hepatol 2013;59:709–716
19. Marcellin P, Buti M, Krastev Z, de Man RA, Zeuzem S, Lou L et al. Kinetics of hepatitis B surface antigen loss in patients with HBeAg-positive chronic hepatitis B treated with tenofovir disoproxil fumarate. J Hepatol 2014;61(6):1228–1237. doi:10.1016/j.jhep.2014.07.019